论文部分内容阅读
目的观察重组人干扰素α2b雾化治疗毛细支气管炎的临床疗效、对肺功能的影响及治疗后喘息情况。方法收集2015年1月至2015年4月于重庆医科大学附属儿童医院呼吸中心门诊诊断的毛细支气管炎患儿100例,男74例,女26例。分两组,A组61例,予重组人干扰素α2b 100万单位加生理盐水1 m L溶解后,雾化吸入15~20 min,每天1次,疗程5~7 d;B组39例为对照组。两组均予止咳化痰、解痉平喘对症治疗。治疗7 d后进行两组症状体、征消失时间及组间临床疗效比较。治疗后2个月行婴儿潮气呼吸肺功能检查,观察两组呼吸频率(RR)、潮气量(VT)、达峰时间比(TPTEF/TE)、达峰容积比(VPEF/VE)变化。并于6个月后电话随访患儿病后再次喘息情况。结果 A组咳嗽、喘憋、肺部哮鸣音消失时间均早于B组(P<0.05)。A组治愈率(55.7%)高于B组(17.9%),差异有统计学意义(χ2=14.044,P<0.05)。潮气呼吸肺功能比较提示,A组小气道阻塞轻于B组(P<0.05)。A、B组再次喘息率分别为21.3%,28.2%,差异无统计学意义(χ2=0.620,P>0.05)。两组均未见局部刺激、皮疹、发热、呕吐等不良反应。结论重组人干扰素α2b雾化吸入治疗毛细支气管炎临床疗效好,临床症状、体征消失早,呼吸肺功能检查小气道阻塞情况恢复较好,但对病后再次喘息的发生无明显改善。
Objective To observe the clinical efficacy of recombinant human interferon α2b atomization in the treatment of bronchiolitis, the effects on lung function and wheezing after treatment. Methods A total of 100 cases of bronchiolitis diagnosed in the respiratory center of Children’s Hospital of Chongqing Medical University from January 2015 to April 2015 were collected, including 74 males and 26 females. Divided into two groups, A group of 61 cases, to recombinant human interferon α2b 1000000 units plus normal saline 1ml dissolved, inhalation 15 ~ 20min, day 1, treatment for 5 ~ 7 d; B group 39 cases were Control group. Both groups were cough and phlegm, antispasmodic anti-asthma symptomatic treatment. After 7 days of treatment, two groups of symptoms, signs of disappearance of time and comparison of clinical efficacy between groups. Respiratory rate (RR), tidal volume (VT), peak time ratio (TPTEF / TE) and peak volume ratio (VPEF / VE) were observed in two months after treatment. And after 6 months of telephone follow-up children with wheezing again after the illness. Results A group of cough, wheezing, pulmonary wheeze disappeared earlier than the B group (P <0.05). The cure rate of group A (55.7%) was higher than that of group B (17.9%), the difference was statistically significant (χ2 = 14.044, P <0.05). Comparison of tidal respiratory function suggested that small airway obstruction in group A was lighter than that in group B (P <0.05). The wheezing rates again in group A and group B were 21.3% and 28.2% respectively, with no significant difference (χ2 = 0.620, P> 0.05). No local stimulation in both groups, rash, fever, vomiting and other adverse reactions. Conclusions The therapeutic effect of recombinant human interferon α2b aerosol inhalation on bronchiolitis is good, the clinical symptoms and signs disappear early, and the recovery of small airway obstruction in respiration lung function recovery is better, but there is no obvious improvement on the occurrence of respite wheezing after illness.